ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-OR30

The Risk of CKD in Lithium-Treated Individuals

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Gislason, Gisli, Heilbrigdisvisindasvid - Haskoli Island, Reykjavik, Iceland
  • Indridason, Olafur S., Landspitali, Reykjavik, Capital, Iceland
  • Sigurdsson, Engilbert, Heilbrigdisvisindasvid - Haskoli Island, Reykjavik, Iceland
  • Palsson, Runolfur, Heilbrigdisvisindasvid - Haskoli Island, Reykjavik, Iceland

The use of lithium may contribute to chronic kidney disease (CKD) but studies have yielded conflicting results. The aim of this study was to examine the risk of developing CKD stage 3 and above among persons treated with lithium.


This was a retrospective cohort study of all persons in Iceland using lithium in the years 2008-2018. Patients with affective disorders (ICD-10 codes F30-F39) attending the outpatient clinics of the Landspitali–The National University Hospital Mental Health Services in 2014-2016 who had not been prescribed lithium served as controls. CKD stages 3-5 was defined as eGFR <60 ml/min/1.73 m2,eGFR was calculated using the serum creatinine (SCr) based CKD-EPI equation. Individuals with fewer than 2 SCr measurements during the study period and those with CKD stages 3-5 prior to 2008 were excluded. Cox regression was performed to assess the risk of CKD associated with lithium treatment in a time dependent manner, adjusting for important confounding factors where acute kidney injury (AKI), hypertension, diabetes mellitus (DM) and cardiovascular diseases were treated as time-dependent covariates.


A total of 2760 persons received lithium treatment during the study period, of whom 2046 (74.1%) were included in the study. Of those, 221 (10.9%) developed CKD stages 3-5. Of the 1615 persons in the control group, 1220 (75.6%) were included, of whom 39 (3.2%) developed CKD 3-5. Lithium use was associated with incident CKD (hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.37–2.74) in the adjusted model. Age per year (HR 1.03, 95% CI 1.02–1.04), initial eGFR per mL/min/1.73 m2 (HR 0.92-0.96, 95% CI 0.92–0.99), DM (HR 1.73, 95% CI 1.15–2.48) and AKI (HR 1.89, 95% CI 1.32–2.74) were other significant CKD risk factors. When compared to individuals not exposed to lithium the HR for CKD in adjusted analysis was 1.24 (95% CI 0.81–1.89) for those with mean lithium concentration of 0.3-0.59 mmol/L, 2.88 (95% CI 1.97–4.20) for those with mean lithium concentration of 0.6-0.79 mmol/L, and 5.23 (95% CI 3.31-8.26) for those with mean lithium concentration of 0.8-0.99 mmol/L.


Long-term lithium use is associated with risk of CKD in a concentration-dependent manner among patients with bipolar and unipolar mood disorders. Therefore, the mean blood concentration of lithium should be kept as low as possible for adequate mood stabilization and treatment.


  • Government Support – Non-U.S.